AB Science announces publication of a significant response case with masitinib in a patient with c-KIT-mutated metastatic melanoma a patient with of c-KIT-mutated metastatic melanoma

Source: Pharmiweb.com. December 2015

Paris, 2 December 2015, 7pm

AB Science announces publication of a significant response case with masitinib in a patient with c-KIT-mutated metastatic melanoma

First report of brain metastases responding to masitinib

On-going phase 3 with masitinib in c- KIT-mutated metastatic melanoma
will have interim analysis in 2017

AB Science SA (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announces the publication of an article entitled “Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report".

The authors present the first patient with c-Kit exon 11 mutated primary esophageal melanoma, metastasizing into visceral organs and to the brain and treated with oral tyrosine kinase inhibitor masitinib. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life.